Abstract
When replete with zinc and copper, amyotrophic lateral sclerosis (ALS)-associated mutant SOD proteins can protect motor neurons in culture from trophic factor deprivation as efficiently as wild-type SOD. However, the removal of zinc from either mutant or wild-type SOD results in apoptosis of motor neurons through a copper- and peroxynitrite-dependent mechanism. It has also been shown that motor neurons isolated from transgenic mice expressing mutant SODs survive well in culture but undergo apoptosis when exposed to nitric oxide via a Fas-dependent mechanism. We combined these two parallel approaches for understanding SOD toxicity in ALS and found that zinc-deficient SOD-induced motor neuron death required Fas activation, whereas the nitric oxide-dependent death of G93A SOD-expressing motor neurons required copper and involved peroxynitrite formation. Surprisingly, motor neuron death doubled when Cu,Zn-SOD protein was either delivered intracellularly to G93A SOD-expressing motor neurons or co-delivered with zinc-deficient SOD to nontransgenic motor neurons. These results could be rationalized by biophysical data showing that heterodimer formation of Cu,Zn-SOD with zinc-deficient SOD prevented the monomerization and subsequent aggregation of zinc-deficient SOD under thiol-reducing conditions. ALS mutant SOD was also stabilized by mutating cysteine 111 to serine, which greatly increased the toxicity of zinc-deficient SOD. Thus, stabilization of ALS mutant SOD by two different approaches augmented its toxicity to motor neurons. Taken together, these results are consistent with copper-containing zinc-deficient SOD being the elusive “partially unfolded intermediate” responsible for the toxic gain of function conferred by ALS mutant SOD.
Keywords: Amyotropic Lateral Sclerosis (Lou Gehrig Disease), Apoptosis, Neurodegeneration, Nitric Oxide, Superoxide Dismutase (SOD), Fas, Motor Neuron, Peroxynitrite
Introduction
Mutations to copper/zinc superoxide dismutase (SOD)4 are the most common genetic cause of the familial form of amyotrophic lateral sclerosis (ALS) (1, 2). Although transgenic expression of these mutant SOD genes in mice and rats is sufficient to produce a progressive motor neuron disease that mimics human pathology (3), the toxic mechanisms remain obscure. Primary motor neuron cultures have proven to be a powerful model to elucidate the toxic gain of function conferred by ALS mutations to SOD and to determine the underlying cell death pathways. Motor neurons isolated from transgenic mice carrying ALS mutant SOD are fully viable in culture (4, 5) but undergo apoptosis after incubation with low, physiologically relevant concentrations of exogenous nitric oxide (50–100 nm). This remains the most direct evidence that mutant SOD can become directly toxic to motor neurons but also demonstrates that expression of mutant SOD alone may not be sufficient to be toxic to motor neurons.
The concentrations of nitric oxide used to induce death of ALS-SOD-expressing motor neurons were not injurious to motor neurons isolated from transgenic mice expressing wild-type SOD and are even trophic to nontransgenic motor neurons (6). Over the past decade, we have accumulated considerable evidence that the reaction of nitric oxide with superoxide (O2⨪) to form peroxynitrite (ONOO−) is responsible for initiating apoptosis in motor neurons. Superoxide generation can be stimulated in motor neurons by activation of the p75 low affinity neurotrophic receptor, which in turn stimulates a ceramide-dependent pathway (7). Motor neurons themselves can produce sufficient endogenous nitric oxide to activate the death cascade by inducing neuronal nitric-oxide synthase (6, 8, 9). Activation of the Fas receptor strongly up-regulates neuronal nitric-oxide synthase before inducing motor neuron death (4). Alternatively, nitric oxide can also be generated by surrounding cells such as astrocytes in co-culture and diffuse into motor neurons to activate apoptosis. The evidence for superoxide reacting with nitric oxide comes from multiple studies showing that motor neuron death can be prevented either by superoxide scavengers, inhibitors of nitric oxide synthesis, or peroxynitrite scavengers (6, 9–11). In addition, tyrosine nitration, a biomarker of peroxynitrite formation, closely correlates with motor neuron death and is prevented by the same compounds that inhibit the activation of the death cascades (5, 8, 10, 12). We have recently shown that nitration mediated by peroxynitrite may be directly involved in activating motor neuron death (12). Tyrosine nitration has been found in the spinal cord of both transgenic models of ALS and in its human victims (13–17).
As the most efficient scavenger of superoxide in the cytoplasm, Cu,Zn-SOD is an important defense against peroxynitrite-induced motor neuron death. Delivery of Cu,Zn-SOD intracellularly into cultured motor neurons protects them from death induced by trophic factor deprivation. Notably, the intracellular release of eight different ALS mutant Cu,Zn-SODs was found to be just as protective as Cu,Zn-SODWT in preventing motor neuron death induced by trophic factor deprivation (11). Metal binding to the SOD protein is essential for its biological function. Many mutant SODs bind copper and zinc and maintain full superoxide scavenging activity when expressed as recombinant proteins or in vivo (18, 19). However, ALS mutant SODs have a 5–50-fold lower affinity for zinc than the wild-type enzyme (20, 21). Copper remains tightly bound, favoring the formation of zinc-deficient SOD. The loss of zinc disorganizes two loops that form the active site, leaving the copper more accessible to cellular molecules and able to catalyze adverse oxidative reactions including tyrosine nitration (11, 22). We previously showed that zinc-deficient SOD induces a peroxynitrite-dependent death cascade in motor neurons that closely paralleled trophic factor deprivation (11). The primary distinction was that the toxicity of zinc-deficient SOD could be prevented by the copper chelators neocuproine and bathocuproine, whereas these compounds do not protect nontransgenic motor neurons from death induced by trophic factor withdrawal.
Although overexpression of wild-type Cu,Zn-SOD (SODWT) in animal models generally provides protection against cerebral ischemia and excitotoxicity (23, 24), recent studies have shown that SODWT increases mutant SOD toxicity in vivo (25–27), even in the SODG85R transgenic mice (28), although it was previously reported that the expression of Cu,Zn-SODWT had no effect on disease progression in a different SODG85R line (29). The mechanism for how co-expression of Cu,Zn-SODWT increases the toxicity of mutant SOD is controversial, with some groups arguing that aggregation plays a role (27, 30) and with others concluding that increased solubility of the enzyme contributes to the enhanced toxicity (26, 31, 32).
Understanding the basis for early onset and faster disease progression is important because the vast majority of familial SOD patients are heterozygotes, and the SOD mutations generally exhibit dominant inheritance. Here, we used motor neurons isolated for ALS mutant-expressing rats and mice to investigate whether the death cascade induced by nitric oxide was similar to that induced by intracellular delivery of zinc-deficient SOD. The investigation was extended to determine whether subunits of Cu,Zn-SOD can increase the toxic gain-of-function of mutant SOD as well as the toxicity of zinc-deficient SOD.
MATERIALS AND METHODS
Isolation of Motor Neurons
Motor neurons were prepared as described previously (8, 33). Briefly, isolated ventral spinal cords from embryonic day 15 rat embryos were trypsinized, and the tissue was disaggregated by trituration. The cell suspension was centrifuged on top of a 6% OptiPrep cushion (Sigma), and the motor neurons were removed from the interface. Motor neurons were further purified by magnet-assisted cell separation (Miltenyi Biotec, Auburn, CA) using the IgG 192 antibody against p75 low affinity neurotrophin receptor (Chemicon-Milliport, Billerica, MA). Motor neurons were plated on 4- or 96-well plates coated with poly-dl-ornithine and laminin (Sigma) at a density of 1500 and 500 cells/well, respectively. The motor neurons were maintained in NeurobasalTM medium supplemented with B27, heat-inactivated horse serum, glutamine, glutamate, 2-mercaptoethanol (all from Invitrogen), and trophic factors (1 ng/ml brain-derived neurotrophic factor, 0.1 ng/ml glial-derived neurotrophic factor, 10 ng/ml cardiotrophin-1) and incubated in a 5% CO2 humidified atmosphere at 37 °C.
Treatment of Motor Neurons with SOD
SOD was delivered utilizing either Chariot (Active Motif, Carlsbad, CA) or pH-sensitive liposomes. Cu,Zn-SOD or zinc-deficient SOD was diluted in sterile H2O at a final concentration of 5 μg/ml at room temperature. If Cu,Zn-SOD and zinc-deficient SOD were added together, they were incubated at room temperature for 30 min to allow heterodimer formation. Chariot (3.75 μl/ml) was diluted in H2O and added to the SOD protein for 30 min to allow complexes to form. After 24 h in culture, the medium was aspirated and replaced with 100 μl of Opti-MEM transfection medium at 37 °C (Invitrogen) containing the mixture Chariot and SOD to be delivered. The cells were incubated at 37 °C for 1 h, at which time 100 μl of 2× NeurobasalTM medium (Invitrogen) plus or minus trophic factors was added to each well and then further incubated for 24 h at 37 °C.
Liposomes were prepared by extrusion using an extruder from Lipex Biomembranes Inc. (Vancouver, Canada), as described (10). Briefly, dioleoylphosphatidyl-ethanolamine (35 μmol) and dioleoylglycerosuccinate (35 μmol; Avanti Polar Lipids, Alabaster, AL) were dried under nitrogen followed by vacuum and then hydrated with 1 ml of 210 mm sucrose in 7 mm HEPES, pH 8.5, for 24–48 h at 37 °C. Human SOD (5 mg in 50 μl) was added to 250 μl of the hydrated lipids. The mixture was vortexed, and the extrusion was performed for 10–15 cycles through a 0.6-μm Nucleopore membrane (Millipore Corp., Bedford, MA). The liposomes were centrifuged at 150,000 × g for 1 h, rinsed once with fresh sucrose-HEPES buffer, and resuspended in 250 μl of the same solution. Typically 2.5–3 mg of SOD were incorporated into liposomes, and 1 μl of liposomes were added per well, which corresponds to 50 mmol of lipids and 10 μg of SOD. The liposomes were added to 24-h-old motor neuron cultures after replacing the culture medium with fresh NeurobasalTM containing B27 supplement, glutamine, 2-mercaptoethanol, and the corresponding trophic factors. Horse serum and glutamate were omitted from the medium.
Immunofluorescence
The motor neurons were stained as described previously (8). Briefly, the medium was removed and replaced with L15 plus 4% paraformaldehyde for 2 min on ice. The cells were rinsed three times with L15 and incubated for 20 min with 4% paraformaldehyde. After rinsing, the slides were incubated with 50 mm lysine, 0.1% Triton X-100 in PBS for 15 min at room temperature. The cells were blocked using 5% BSA at room temperature for 1 h. Primary antibodies were incubated in blocking solution in a humidified chamber at 4 °C overnight and rinsed three times for 5 min with PBS. Fluorescent secondary antibodies were added in blocking solution for 1 h at room temperature protected from light. The cells were rinsed three times for 5 min with PBS and with water once before being mounted using ProLong Gold with 4′,6-diamidino-2-phenylindole (Molecular Probes-Invitrogen).
Motor Neuron Survival
Motor neuron survival was determined either by counting cells with neurites longer than four soma diameters under a phase contrast microscope in four-well plates as described previously (8) or by high throughput image capture and analysis in 96-well plates using a Flash CytometerTM (Trophos, Marseilles, France) as reported before (34). For high throughput image capture, motor neurons plated in black 96-well plates coated with poly-d-ornithine and laminin (Greiner Bio-one, Monroe, NC) were treated with calcein-AM (Molecular Probes-Invitrogen) in L15 medium (Invitrogen) for 1 h at 37 °C. Fifteen μl/well of 100 mg/ml of hemoglobin in PBS was added to quench extracellular calcein, and the plates were read using a Flash Cytometer. Cell counts were obtained and are represented as percentages of survival relative to the survival in the presence of neurotrophic factors (1 ng/ml brain-derived neurotrophic factor, 0.1 ng/ml glial-derived neurotrophic factor, and 10 ng/ml cardiotrophin-1) used as 100% survival to standardize between experiments as described previously (8). Image analysis was performed using the TinaTM software (Trophos) or the MetamorphTM software (Molecular Devices, Downingtown, PA). The results for the different treatments were equivalent using liposomes or Chariot and either method of quantifying motor neuron survival.
Kinetics of SOD Dimer Formation
Sedimentation velocity ultracentrifugation experiments were performed in a Beckman Optima XL-A analytical ultracentrifuge as described previously (22). Buffer densities and viscosity corrections were made as described previously (35). The protein sequence was used to estimate the partial specific volume of SOD (0.725 cm3 g−1) (22, 36). Sedimentation velocity centrifugation was performed at 20 °C using an AN-60Ti rotor and double-sector charcoal/Epon-filled centerpieces. SOD samples (10 μm, A230 = 0.8) were centrifuged at 42,000 rpm. Typically, three 360-μl samples of 20 μm SOD (or 10 μm Cu,Zn-SOD plus 10 μm zinc-deficient D124N SOD) were centrifuged. Scans were collected with absorbance optics at wavelengths between 230 and 280 nm. The radial step size was 0.001 cm, and each c versus r data point was the average of 15 independent measurements. Wavelengths were chosen such that the absorbance never exceeded 1.0. Using UltraScan software, equilibrium data were fit to multiple models using global fitting. The most appropriate model was chosen based on the goodness-of-fit and inspection of the residual patterns.
Gel filtration experiments were performed by incubating SOD for 1 or 24 h with increasing concentrations of DTT (0–100 mm). To ensure that the DTT was fully reduced, tributylphosphine (100 μl) was added to 0.5 m DTT (400 μl). The solution was mixed gently, and then 1-bromo-3-chloropropane (100 μl) was added. The reduced DTT was collected after separation into an upper phase. The concentration of SOD used was 20 μm for all cases, whereas the heterodimer samples consisted of 10 μm zinc-deficient D83S/C111S SOD plus 10 μm wild-type Cu,Zn-SOD. After incubation for either 1 or 24 h at room temperature, the samples were separated using a TosoHaasTM G3000SWXL column with 100 mm NaPO4, pH 7.0, as the running buffer and a flow rate of 1.0 ml/min. Elution of protein was monitored at 214 nm, and the percentage of monomer was determined by dividing the area of the monomer by the total area of dimer and monomer.
Statistical Analysis
The statistical analysis was performed using PrismTM 5.0b software (GraphPad Software, Inc.). Multiple comparisons were performed using one- or two-way ANOVA, depending on the experimental design, followed by post-hoc test. In specific groups that did not pass the homoscedasticity test, the statistical analysis was performed using the Kruskal-Wallis test. The values were considered significantly different when p < 0.05. Dose-response curves were fitted to a sigmoid curve when possible using nonlinear regression without restrictions. All of the experiments were repeated at least three times with each condition performed at least in duplicate in each experiments.
RESULTS
Copper Chelation Protects Motor Neurons Expressing ALS Mutant SODG93A from Death Induced by Nitric Oxide
Motor neurons isolated from G93A transgenic rats (37) were exposed to low steady state concentrations of nitric oxide (∼100 nm) produced by the nitric oxide donor DETANONOate (20 μm) for 24 h in the presence or absence of the specific Cu1+ chelator bathocuproine (50 μm). Bathocuproine significantly reversed SODG93A transgenic motor neuron death induced by nitric oxide (Fig. 1A). The metalloporphyrin peroxynitrite and superoxide scavengers MnTBAP (100 μm) and FeTCPP (10 μm) both prevented nitric oxide-induced transgenic motor neuron death (Fig. 1A). Similar results were obtained using motor neurons isolated from SODG93A transgenic mice (not shown). Incubation of motor neurons carrying the G93A SOD mutation with exogenous nitric oxide showed increased nitrotyrosine immunoreactivity, which was reversed by treatment with bathocuproine or with MnTBAP (Fig. 1B).
Cu,Zn-SOD Increases the Toxic Effect of Nitric Oxide on G93A Mutant SOD Transgenic Motor Neurons
To further test the role of superoxide on nitric oxide toxicity, Cu,Zn-SODWT (1 μg) was released intracellularly into motor neurons from SODG93A transgenic as well as nontransgenic rat motor neurons. SOD was delivered with the membrane-permeating agent Chariot, and the treated motor neurons were also incubated with the nitric oxide donor DETANONOate (20 μm). The intracellular delivery of SOD protein into motor neurons was verified by immunofluorescence (supplemental Fig. S1). The prediction of the experiment was that if superoxide was involved, Cu,Zn-SOD should protect against nitric oxide-induced toxicity in transgenic motor neurons. Paradoxically, intracellular delivery of Cu,Zn-SODWT enhanced nitric oxide-induced transgenic motor neuron death in a dose-dependent manner but had no effect on motor neuron survival in the absence of nitric oxide (Fig. 2A). SOD added to the medium without Chariot, intracellular release of apoSOD, BSA, or copper-loaded BSA did not affect motor neuron survival, whether or not the cells were exposed to nitric oxide (not shown). In agreement with previous reports (5, 8, 10, 38), nitric oxide did not decrease survival of nontransgenic motor neurons even with intracellular delivery of Cu,Zn-SODWT (Fig. 2B). Conversely, scavenging of superoxide and peroxynitrite with MnTBAP (100 μm) and FeTCPP (10 μm) and copper chelation with bathocuproine (50 μm) reversed SODG93A transgenic motor neuron death induced by nitric oxide plus Cu,Zn-SODWT (Fig. 2C) to the same extent as with nitric oxide alone (Fig. 1).
Cu,Zn-SOD Increased Zinc-deficient SOD Toxicity on Nontransgenic Motor Neurons
To investigate the effect of Cu,Zn-SOD on zinc-deficient SOD-induced motor neuron death, experiments were performed using pH-sensitive liposomes rather than Chariot to deliver the enzyme (10, 39). The use of liposomes was necessary to prevent the surreptitious binding of zinc to zinc-deficient SOD that would occur in the culture medium if the Chariot method was used (11). Liposomes loaded with 10 μg of either zinc-deficient SODWT, SODA4V, or SODD124N all induced ∼50% motor neuron death after 24 h in culture (Fig. 3) as previously reported (11). When half of the zinc-deficient SODWT was replaced with Cu,Zn-SODWT (5 μg of each enzyme), motor neuron death increased from ∼50% to >85% (Fig. 3A). The enhanced toxicity was independent of whether zinc-deficient SODWT and Cu,Zn-SODWT were encapsulated in the same liposome preparation or the zinc-deficient, and Cu,Zn-SODs were added to cells in separately prepared liposomes (Fig. 3B). The enhanced toxicity was also independent of whether the zinc-deficient SOD was a wild-type or an ALS mutant protein (Fig. 3C). Thus, Cu,Zn-SODA4V plus zinc-deficient SODWT was just as toxic as Cu,Zn-SODWT plus zinc-deficient SODA4V (Fig. 3C).
The same results were obtained using human SOD in which the aspartate residue in position 83 was mutated to serine (SODD83S). This mutation disrupts the binding of zinc without affecting the binding of copper (22). Because this mutant protein will not rebind zinc in culture medium, it could be delivered with Chariot. The effects of releasing the zinc-deficient SODD83S and Cu,Zn-SOD with Chariot were indistinguishable from those using liposomes for intracellular delivery (see Fig. 5 and supplemental Fig. S2).
To determine whether superoxide and peroxynitrite production were necessary for the enhanced toxicity of zinc-deficient SOD in the presence of Cu,Zn-SOD, we investigated the effect of metalloporphyrins on motor neuron survival. Both MnTBAP (100 μm) and FeTCPP (10 μm) reversed motor neuron death induced by trophic factor deprivation, intracellular release of zinc-deficient SOD, and zinc-deficient SOD plus Cu,Zn-SOD (Fig. 4). These results show that motor neuron death triggered by combining zinc-deficient SOD with Cu,Zn-SOD involved the same mechanism as the enhanced cell death observed when Cu,Zn-SOD was delivered to transgenic SODG93A motor neurons treated with nitric oxide.
Zinc-deficient SOD Toxicity Is Mediated by Activation of the Fas Pathway
Nitric oxide-induced mutant SOD transgenic motor neuron death requires activation of the Fas death receptor and peroxynitrite production (4, 5). Because copper chelation as well as scavenging of superoxide and peroxynitrite prevented the susceptibility of transgenic mutant SOD motor neurons to nitric oxide as shown in Fig. 1, we asked whether activation of the Fas pathway was necessary for zinc-deficient SOD to induce motor neuron death. Incubation of motor neurons with the Fas receptor decoy Fas:Fc (1 μg/ml) prevented motor neuron death induced by trophic factor deprivation (Fig. 5A), as previously reported (33). The same concentration of Fas:Fc prevented zinc-deficient SODD83S-induced motor neuron death (Fig. 5B). Furthermore, the enhanced motor neuron death triggered by simultaneous incubation with both zinc-deficient SODD83S and Cu,Zn-SODWT was also prevented by incubation with Fas:Fc (Fig. 5C). It has been previously shown that Fas receptor activation in motor neurons leads to phosphorylation and activation of the p38 MAPK, which is necessary for neuronal NOS induction and nitric oxide production (5). Inhibition of p38 MAPK with SB203580 (5 μm) prevented the induction of motor neuron death by zinc-deficient SODD83S and zinc-deficient SODD83S plus Cu,Zn-SODWT (Fig. 6), which is consistent with the activation of the Fas pathway previously reported in the death of ALS mutant transgenic motor neurons (4, 5). The JNK MAPK pathway has been implicated as an upstream regulator of FasL expression (40). Two structurally different JNK inhibitors, JNK II inhibitor (1 μm) and JNK III inhibitor (1 μm), prevented motor neuron death induced by trophic factor deprivation (Fig. 7A), as expected from previous reports using motor neurons isolated from ALS mutant SOD transgenic mice (5, 41, 42). These same inhibitors prevented motor neuron death induced by zinc-deficient SODD83S (Fig. 7B) and zinc-deficient SODD83S plus Cu,Zn-SODWT (Fig. 7C).
Nitric Oxide, Peroxynitrite, and Tyrosine Nitration Are Necessary for Zinc-deficient SOD-induced Motor Neuron Death
Activation of the Fas pathway in motor neurons leads to the induction of NOS, nitric oxide production, and peroxynitrite formation (5), as is the case for zinc-deficient SOD (11) and SODG93A transgenic motor neurons treated with exogenous nitric oxide (4). Inhibition of nitric oxide production with l-NAME protected motor neurons treated with zinc-deficient SODD83S alone (Fig. 8A) or in combination with Cu,Zn-SODWT (Fig. 8B). The protective effect of l-NAME was abolished by low steady state concentrations of nitric oxide (100 nm) produced by DETANONOate (20 μm), which supports the conclusion that the protection afforded by l-NAME was due to inhibition of nitric oxide production (Fig. 8, A and B).
We have previously shown that tyrosine-containing peptides inhibit peroxynitrite-mediated apoptosis and tyrosine nitration but do not directly scavenge peroxynitrite or prevent thiol oxidation (12). These peptides also do not prevent apoptosis induced by hydrogen peroxide or staurosporine (12). Incubation of motor neurons with the most effective of the nitration-inhibiting peptides RYEYA (0.5 mm) and EYTA (0.5 mm) prevented motor neuron death induced by zinc-deficient SODWT (Fig. 8C). The same peptides containing phenylalanine (RFEFA or EFTA) were not protective; these analogs were previously shown to not be effective competitive inhibitors of tyrosine nitration (12). These results extend our previous observations that tyrosine nitration plays a role in the induction of motor neuron death by trophic factor deprivation to include death induced by zinc-deficient SOD.
Cu,Zn-SOD Dimers with Zinc-deficient SOD Increases Protein Stability
Zinc-deficient SODD83S forms heterodimers with Cu,Zn-SODWT subunits with a half-life of 17 min at 37 °C (22). In the absence of a sulfhydryl-reducing agent, both Cu,Zn-SODWT and zinc-deficient SODD83S existed solely as dimers during sedimentation velocity ultracentrifugation (Fig. 9A). In the presence of the thiol-reducing agent DTT (1 mm), zinc-deficient SODD83S existed as 60% monomer, 30% dimer (30%), and 10% in a dynamic exchange state that was intermediate between monomer and dimer (Fig. 9B). Under the same conditions, Cu,Zn-SODWT existed as 90% dimer, 10% was in a dynamic exchange state, and monomer was undetectable. When Cu,Zn-SOD and zinc-deficient SOD were combined, 10% was monomeric with 50% in the dynamic exchange state (Fig. 9B). The susceptibility to form monomers of Cu,Zn-SODWT, zinc-deficient SODD83S, and the mixture of Cu,Zn-SODWT and zinc-deficient SODD83S in the presence of a reducing agent was further investigated by size exclusion chromatography. A 670-fold lower concentration of DTT was necessary to dissociate 50% of the zinc-deficient SODD83S into monomers compared with Cu,Zn-SODWT after 24 h of incubation (Fig. 9D and Table 1). When coincubated with Cu,Zn-SODWT, 25-fold more DTT was needed at 24 h to form monomers than when zinc-deficient SODD38S was incubated alone (Fig. 9D and Table 1).
TABLE 1.
DTT concentration |
||
---|---|---|
1 h | 24 h | |
mm | ||
Cu,Zn-SODWT | 100 | 100 |
Zn(−)SODD83S | 1.91 | 0.15 |
Cu,Zn-SODWT + Zn(−)SODD83S | 5.4 | 3.8 |
Mutation of Cysteines 6 and 111 Enhanced Zinc-deficient SOD Toxicity
The toxic gain-of-function of mutant SOD and the enhanced toxicity by overexpression of Cu,Zn-SODWT observed in animal models of ALS have been attributed to the formation of intermolecular disulfide bounds between the SOD monomers (27). We tested the role of thiol oxidation in the toxicity of zinc-deficient SOD by mutating both cysteine 6 to alanine and cysteine 111 to serine in SODWT and SODA4V. Removal of these two cysteines is known to make the unfolding of SOD protein with denaturants reversible in vitro (43). When C111S is mutated in the SODA4V, the protein remains soluble, whereas mutation of Cys6 to alanine did not prevent the formation of inclusion bodies (Fig. 10). Mutation of Cys111 to serine allowed the soluble expression of over a dozen different ALS-associated mutant proteins in Escherichia coli (not shown).
Cu,Zn-SODWT carrying the C6A and C111S mutations did not affect motor survival when delivered to motor neurons using pH-sensitive liposomes. In contrast, zinc-deficient SODC6A,C111S showed increased toxicity when compared with zinc-deficient SODWT (Fig. 11A). Similarly, zinc-deficient SODA4V,C6A,C111S was substantially more toxic than zinc-deficient SODA4V and produced the same level of motor neuron death as zinc-deficient SODA4V plus Cu,Zn-SODWT (Fig. 11B). As is the case for Cu,Zn-SODC6A,C111S, Cu,Zn-SODA4V,C6A,C111S was not toxic to motor neurons when released using liposomes (Fig 11B). Scavenging of superoxide and inhibition of NOS were both protective for motor neurons treated with zinc-deficient SODA4V,C6A,C111S (Fig. 11C). Furthermore, simultaneous incubation of motor neurons with the Cu,Zn-SODA4V,C6A,C111S and tyrosine-containing peptides prevented motor neuron death (Fig. 11D).
DISCUSSION
A unique advantage of motor neuron cultures over animal ALS models is the ability to deliver SOD proteins with well defined metal contents to evaluate their potential toxic as well as protective properties. This allowed the death pathways of motor neurons isolated from SODG93A-expressing transgenic rats to be directly compared with the death pathways induced by the direct delivery of zinc-deficient SOD protein to nontransgenic motor neurons (11). In both models of SOD malfunction, cell death could be blocked by specific chelators that are able to selectively remove copper from zinc-deficient SOD in vitro (11). Low concentrations of nitric oxide were also required for cell death in both models, but these same concentrations were nontoxic for motor neurons isolated from wild-type SOD-expressing motor neurons or nontransgenic motor neurons treated with Cu,Zn-SOD. Exposure to nitric oxide in both models resulted in increased tyrosine nitration, whereas agents that either scavenge peroxynitrite or act as competitive inhibitors of tyrosine nitration were protective. Fas is activated and required for death in both models. These results are consistent with the toxic gain-of-function in both models of SOD malfunction activating the same death pathway. Furthermore, the death pathway induced in both models converges with the motor neuron death pathway triggered by trophic factor deprivation, by reactive astrocytes in co-culture, or by NGF activation of the p75 low affinity neurotrophin receptor through the formation of peroxynitrite (8, 41, 44).
The parallels between motor neuron death induced by zinc-deficient SOD and by SODG93A expression extend to the paradoxical observation that delivery of Cu,Zn-SOD protein dramatically enhanced death in both models. These results also closely parallel results obtained from SOD transgenic mice, where co-expression of SODWT with ALS mutant SOD has been repeatedly observed to accelerate the onset of ALS symptoms and decrease survival (25–27). The A4V mutation expressed in mice has only been reported to be toxic in mice when co-expressed with wild-type SOD (27). Although co-expression of SODWT with one SODG85R mouse line was reported to not affect disease progression (29), SODWT has since been reported to accelerate disease development in a different SODG85R transgenic mouse line (28). Understanding the basis for wild-type SOD enhancing of mutant SOD toxicity is potentially important for the human disease because all known SOD mutations can be dominant, implying that a wild-type allele will be expressed along with the mutant allele in the vast majority of familial SOD patients.
The mechanisms for the increased toxicity resulting from SODWT co-expression are controversial. Furukawa et al. (30) found that co-expression resulted in greater thiol cross-linking of SOD into higher molecular weight aggregates in the terminal stages of the disease. Other recent studies have found SODWT increases the solubility of mutant SOD and reduced the number of aggregates in vivo during the early stages of the disease (26, 31, 32, 45). Our results with purified motor neurons are more consistent with Cu,Zn-SOD subunits stabilizing the “toxic intermediate” from SODG93A expression as well as direct delivery of zinc-deficient SOD. Previously, we found that zinc-deficient SODWT is just as toxic to motor neurons as zinc-deficient mutant SODs, and conversely mutant Cu,Zn-SODs protected motor neurons from trophic factor withdrawal as well as Cu,Zn-SODWT (10, 11). In the present study, Cu,Zn-SOD subunits enhanced the toxicity of zinc-deficient SOD, even though only half the concentration of each was added, keeping the total amount of SOD equivalent. Furthermore, it did not matter whether the Cu,Zn-containing SOD subunits were wild-type or mutant proteins. Thus, the paradoxical enhancement of toxicity by Cu,Zn-SOD protein suggests that the critical factor resulted from stabilization by zinc rather than being a direct consequence of the protein sequence per se.
The critical role of zinc in maintaining the dimeric structure of SOD offers a direct explanation for how Cu,Zn-SOD subunits can stabilize zinc-deficient SOD, because the zinc binding to loop IV plays a key role in stabilizing the dimer interface of SOD. Loop IV extends from residues 50 to 84, which comprises 23% of the SOD protein and is the longest stretch without a regular secondary structure. Loop IV can be subdivided into three functional segments: the zinc-binding pocket, the dimer interface, and the intramolecular Cys57–Cys146 disulfide bond. These segments interact to modulate the stability of the SOD dimer as well as the binding of the metal co-factors. Biophysical studies on SOD unfolding have also established that zinc-deficient SOD has a greater propensity to exist as a monomer (46). Residues in loop IV form 37% the dimer interface surface area (22, 47). Because SOD is a homodimer, the zinc loop from the opposing monomer contributes another third of the dimer interface. Thus, only a third of the interface will be affected in a heterodimer of zinc-deficient SOD with Cu,Zn-SOD, whereas two-thirds of the dimer interface will be destabilized in a homodimer of zinc-deficient SOD subunits. Consistent with this, the x-ray structure of zinc-deficient homodimeric SOD revealed the largest distortion of the dimer interface that has been reported for any human SOD structure (22).
The dimer interface portion of loop IV is strongly stabilized by the highly unusual and extraordinarily stable intramolecular Cys57–Cys146 disulfide bond (48). It has been shown that either the disulfide bond or zinc bound to loop IV is sufficient to maintain the dimer interface, but the absence of both strongly favors dissociation into monomers (49, 50). SOD is one of a few intracellular proteins whose disulfide bonds remain oxidized within the strong reducing environment of the cytoplasm. The disulfide bond is unusually resistant to reduction in Cu,Zn-SOD because it is buried in a rigid, inaccessible conformation (22, 48, 51). It is more susceptible to reduction in ALS mutant SODs (52–55). The x-ray structure of the zinc-deficient SOD homodimer also revealed that the Cys57–Cys146 disulfide bond becomes flexible and even assumes two distinct conformations in the crystal structure (22). This greater flexibility appears to make the bond more accessible to thiol reductants such as glutathione, because SOD without zinc is well known to become more susceptible to reduction the Cys57–Cys146 bond. The reduction of the disulfide in zinc-deficient SOD further destabilizes loop IV, resulting in the dissolution of the enzyme into monomers. Without the stabilization of the dimer interface, monomeric SOD is known to be particularly susceptible to further unfolding to eventually yield thiol-cross-linked aggregates (3, 56, 57).
From these considerations, the dimer interface of a heterodimeric SOD containing a zinc-deficient monomer plus a Cu,Zn monomer should be substantially stabilized compared with homodimeric zinc-deficient SOD. This was clearly observed in the sedimentation velocity ultracentrifugation experiments, where zinc-deficient SOD became monomeric in the presence of thiol-reducing agents. The addition of Cu,Zn-SOD to zinc-deficient SOD largely eliminated the monomeric species but resulted in an intermediate form consistent with the formation of a dynamic dimeric species with a more rapid subunit exchange than Cu,Zn-SOD dimers. We have previously measured the half-life for exchange between Cu,Zn-SOD and zinc-deficient SOD at 37 °C to be 17 min by differential mobility using gel electrophoresis and 14 min by FRET (22), which corresponds to a rate-limiting step of 7–9 × 10−4 s−1. Making the assumption that the slowest step probably involves the dissociation of Cu,Zn dimers, the rate of exchange is ∼10-fold faster than the rate for the dissociation of Cu,Zn-SODWT dimers of 9 × 10−5 s−1 reported by Rumfeldt et al. (58) and ∼30 times faster than the rate of 3 × 10−5 s−1 reported by Khare et al. (59). Both of the latter rates were measured at 25 °C, which accounts for a substantial part of the difference. The remaining difference may have resulted from the inclusion of 100 mm NaCl to mimic physiological ionic strength in our study. Interestingly, the reassociation of Cu,Zn-SOD monomers to form dimer occurs at a rate of 1.3 × 105 m−1 s−1, whereas apoSOD monomers are reported to reassociate at a diffusion-limited rate of 2 × 109 m−1 s−1 (43, 50). Thus, the greater disorder of the dimer interface in the apoSOD appears to allow SOD monomers to bind to each other more rapidly even though the dimer is not as stable. Similarly, the additional flexibility of loop IV in zinc-deficient SOD might allow for the more rapid recombination with Cu,Zn-SOD monomers that favor heterodimer formation.
Further support for the role of the increasing stability of zinc-deficient SOD in enhancing its toxicity came from substituting the cysteine residues in positions 6 and 111 by alanine and serine in SODWT and SODA4V. These mutations were shown by Getzoff and Tainer and co-workers (60) to increase the apparent thermostability of human SOD, and these forms were used to produce the first x-ray structures of human SOD. Further biophysical studies have shown that removal of the two cysteines in fact slightly decreases the thermodynamic stability of the SOD protein as shown by folding chevron plots (43, 50, 61). Instead, the absence of these cysteines makes the unfolding of the protein reversible by preventing the protein from becoming trapped with non-native disulfide bridges that are more likely to cause the SOD to rapidly aggregate (61). The expression experiments in E. coli show that mutation of just Cys111 to serine was sufficient to eliminate inclusion body formation when mutant SODs are expressed at 37 °C (Fig. 9). In addition, reducing the expression temperature to 18 °C allows for folding of soluble and active mutant SODs without forming inclusion bodies (62). It is also possible to refold mutant SOD trapped in inclusion bodies during growth at 37 °C but only with high concentrations of thiol reductants, supporting the role of nonnative disulfide bridges in promoting insoluble aggregation of SOD (62). Mutation of Cys111 to serine also reduced aggregation of mutant SOD expressed in human embryonic kidney cells (63), showing that the Cys111 cross-links are not necessary for aggregates to form.
One surprising result from the motor neuron experiments is the observation that the zinc-deficient enzyme with the double cysteine mutation was substantially more toxic than the equivalent zinc-deficient SOD with the cysteine residues. When replete with zinc and copper, SODA4V,C6A,C111S showed no toxicity to motor neurons and protected these cells from trophic factor deprivation. The increased toxicity of zinc-deficient SODA4V,C6A,C111S suggests that the proposed copper binding to Cys111 is not necessary for mutant SOD toxicity. In motor neuron cultures, removal of this cysteine increased toxicity of zinc-deficient SOD rather than providing protection.
Recent biophysical studies have now provided a solid structural basis to understand how mutations increase the propensity of SOD to become zinc-deficient, with five groups reporting that ALS-linked mutations accelerate the unfolding of Cu,Zn-SOD protein to produce a moderately stable zinc-deficient SOD intermediate (20, 21, 46, 58, 64). Dissociation of Cu,Zn-SOD into monomers greatly accelerates the loss of zinc (58), as does incubation at moderately acidic pH (46). Destabilization of SODG93A investigated by hydrogen/deuterium exchange with NMR revealed a striking effect on two of the zinc ligands in the zinc-binding loop. The zinc ligand histidine 80 in particular exchanges a 1000-fold faster in SODG93A compared with SODWT, whereas a second zinc ligand exchanges 15-fold faster (65). These studies offer important insights into how a distal mutation can alter the overall protein dynamics of SOD to selectively decrease zinc affinity.
In summary, many studies on mutant SOD proteins conclude that some indeterminate “partially unfolded intermediate” is responsible for the toxic gain of function conferred by ALS mutant SOD. Our results with motor neurons expressing mutant SODG93A are remarkably consistent with the toxic partially unfolded intermediate of SOD being copper-containing, zinc-deficient SOD. Furthermore, the death cascade induced by stabilizing this intermediate shares a common mechanism with motor neuron death cascade induced by other insults such as trophic factor deprivation of nontransgenic motor neurons. Subunits of Cu,Zn-SOD enhanced toxicity in both models of motor neuron death, which can be understood by the key role of the dimer interface in stabilizing zinc-deficient SOD from further unfolding (Scheme 1). The distinguishing prediction from Scheme 1 is that stabilization of zinc-deficient SOD enhances toxicity by preventing its further unfolding and the loss of copper to produce aggregates. These results are consistent with formation of apoSOD and subsequent aggregation being protective by removing zinc-deficient SOD rather than being responsible for the toxic gain-of-function of ALS-linked mutant SOD.
Supplementary Material
Acknowledgment
We thank Dr. Thong C. Ma for suggestions during the preparation of this manuscript.
This work was supported, in whole or in part, by National Institutes of Health Grants NS36761, NS42834 (to A. G. E.), NS058628, AT002034, and ES00240. This work was also supported by funds from the Burke Medical Research Institute, the New York State Spinal Cord Injury Center of Research Excellence, and the Amyotrophic Lateral Sclerosis Association (to J. S. B.).
The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. S1–S3.
- SOD
- superoxide dismutase
- ALS
- amyotrophic lateral sclerosis
- ANOVA
- analysis of variance
- DETANONOate
- (Z)-1-[2-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate
- MnTBAP
- manganese(III) 4,49,40,4-(21H,2H-porphine-5,10,15,20-tetrayl)tetrakis(benzoic acid)
- FeTCPP
- iron 5,10,15,20-tetrakis-4-carboxyphenylporphyrin.
REFERENCES
- 1.Gros-Louis F., Gaspar C., Rouleau G. A. (2006) Biochim. Biophys. Acta. 1762, 956–972 [DOI] [PubMed] [Google Scholar]
- 2.Pasinelli P., Brown R. H. (2006) Nat. Rev. Neurosci. 7, 710–723 [DOI] [PubMed] [Google Scholar]
- 3.Bruijn L. I., Miller T. M., Cleveland D. W. (2004) Annu. Rev. Neurosci. 27, 723–749 [DOI] [PubMed] [Google Scholar]
- 4.Raoul C., Buhler E., Sadeghi C., Jacquier A., Aebischer P., Pettmann B., Henderson C. E., Haase G. (2006) Proc. Natl. Acad. Sci. U.S.A. 103, 6007–6012 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Raoul C., Estévez A. G., Nishimune H., Cleveland D. W., deLapeyrière O., Henderson C. E., Haase G., Pettmann B. (2002) Neuron 35, 1067–1083 [DOI] [PubMed] [Google Scholar]
- 6.Estévez A. G., Spear N., Manuel S. M., Barbeito L., Radi R., Beckman J. S. (1998) Prog. Brain Res. 118, 269–280 [DOI] [PubMed] [Google Scholar]
- 7.Pehar M., Vargas M. R., Robinson K. M., Cassina P., Díaz-Amarilla P. J., Hagen T. M., Radi R., Barbeito L., Beckman J. S. (2007) J. Neurosci. 27, 7777–7785 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Estévez A. G., Spear N., Manuel S. M., Radi R., Henderson C. E., Barbeito L., Beckman J. S. (1998) J. Neurosci. 18, 923–931 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Estévez A. G., Kamaid A., Thompson J. A., Cornwell T. L., Radi R., Barbeito L., Beckman J. S. (2002) Neurosci. Lett. 326, 201–205 [DOI] [PubMed] [Google Scholar]
- 10.Estévez A. G., Sampson J. B., Zhuang Y. X., Spear N., Richardson G. J., Crow J. P., Tarpey M. M., Barbeito L., Beckman J. S. (2000) Free Rad. Biol. Med. 28, 437–446 [DOI] [PubMed] [Google Scholar]
- 11.Estévez A. G., Crow J. P., Sampson J. B., Reiter C., Zhuang Y., Richardson G. J., Tarpey M. M., Barbeito L., Beckman J. S. (1999) Science 286, 2498–2500 [DOI] [PubMed] [Google Scholar]
- 12.Ye Y., Quijano C., Robinson K. M., Ricart K. C., Strayer A. L., Sahawneh M. A., Shacka J. J., Kirk M., Barnes S., Accavitti-Loper M. A., Radi R., Beckman J. S., Estévez A. G. (2007) J. Biol. Chem. 282, 6324–6337 [DOI] [PubMed] [Google Scholar]
- 13.Beal M. F., Ferrante R. J., Browne S. E., Matthews R. T., Kowall N. W., Brown R. H., Jr. (1997) Ann. Neurol. 42, 644–654 [DOI] [PubMed] [Google Scholar]
- 14.Abe K., Pan L. H., Watanabe M., Konno H., Kato T., Itoyama Y. (1997) Neurol. Res. 19, 124–128 [DOI] [PubMed] [Google Scholar]
- 15.Abe K., Pan L. H., Watanabe M., Kato T., Itoyama Y. (1995) Neurosci. Lett. 199, 152–154 [DOI] [PubMed] [Google Scholar]
- 16.Sasaki S., Warita H., Abe K., Iwata M. (2001) J. Neuropathol. Exp. Neurol. 60, 839–846 [DOI] [PubMed] [Google Scholar]
- 17.Casoni F., Basso M., Massignan T., Gianazza E., Cheroni C., Salmona M., Bendotti C., Bonetto V. (2005) J. Biol. Chem. 280, 16295–16304 [DOI] [PubMed] [Google Scholar]
- 18.Borchelt D. R., Lee M. K., Slunt H. S., Guarnieri M., Xu Z. S., Wong P. C., Brown R. H., Jr., Price D. L., Sisodia S. S., Cleveland D. W. (1994) Proc. Natl. Acad. Sci. U.S.A. 91, 8292–8296 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Marklund S. L., Andersen P. M., Forsgren L., Nilsson P., Ohlsson P. I., Wikander G., Oberg A. (1997) J. Neurochem. 69, 675–681 [DOI] [PubMed] [Google Scholar]
- 20.Lyons T. J., Liu H., Goto J. J., Nersissian A., Roe J. A., Graden J. A., Café C., Ellerby L. M., Bredesen D. E., Gralla E. B., Valentine J. S. (1996) Proc. Natl. Acad. Sci. U.S.A. 93, 12240–12244 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Crow J. P., Sampson J. B., Zhuang Y., Thompson J. A., Beckman J. S. (1997) J. Neurochem. 69, 1936–1944 [DOI] [PubMed] [Google Scholar]
- 22.Roberts B. R., Tainer J. A., Getzoff E. D., Malencik D. A., Anderson S. R., Bomben V. C., Meyers K. R., Karplus P. A., Beckman J. S. (2007) J. Mol. Biol. 373, 877–890 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Chan P. H., Kawase M., Murakami K., Chen S. F., Li Y., Calagui B., Reola L., Carlson E., Epstein C. J. (1998) J. Neurosci. 18, 8292–8299 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Maier C. M., Sun G. H., Cheng D., Yenari M. A., Chan P. H., Steinberg G. K. (2002) Neurobiol. Dis. 11, 28–42 [DOI] [PubMed] [Google Scholar]
- 25.Jaarsma D., Haasdijk E. D., Grashorn J. A., Hawkins R., van Duijn W., Verspaget H. W., London J., Holstege J. C. (2000) Neurobiol. Dis. 7, 623–643 [DOI] [PubMed] [Google Scholar]
- 26.Fukada K., Nagano S., Satoh M., Tohyama C., Nakanishi T., Shimizu A., Yanagihara T., Sakoda S. (2001) Eur. J. Neurosci. 14, 2032–2036 [DOI] [PubMed] [Google Scholar]
- 27.Deng H. X., Shi Y., Furukawa Y., Zhai H., Fu R., Liu E., Gorrie G. H., Khan M. S., Hung W. Y., Bigio E. H., Lukas T., Dal Canto M. C., O'Halloran T. V., Siddique T. (2006) Proc. Natl. Acad. Sci. U.S.A. 103, 7142–7147 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Wang L., Deng H. X., Grisotti G., Zhai H., Siddique T., Roos R. P. (2009) Hum. Mol. Genet 18, 1642–1651 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Bruijn L. I., Houseweart M. K., Kato S., Anderson K. L., Anderson S. D., Ohama E., Reaume A. G., Scott R. W., Cleveland D. W. (1998) Science 281, 1851–1854 [DOI] [PubMed] [Google Scholar]
- 30.Furukawa Y., Fu R., Deng H. X., Siddique T., O'Halloran T. V. (2006) Proc. Natl. Acad. Sci. U.S.A. 103, 7148–7153 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Witan H., Kern A., Koziollek-Drechsler I., Wade R., Behl C., Clement A. M. (2008) Hum. Mol. Genet. 17, 1373–1385 [DOI] [PubMed] [Google Scholar]
- 32.Witan H., Gorlovoy P., Kaya A. M., Koziollek-Drechsler I., Neumann H., Behl C., Clement A. M. (2009) Neurobiol. Dis. 36, 331–342 [DOI] [PubMed] [Google Scholar]
- 33.Raoul C., Henderson C. E., Pettmann B. (1999) J. Cell Biol. 147, 1049–1062 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Bordet T., Buisson B., Michaud M., Drouot C., Galéa P., Delaage P., Akentieva N. P., Evers A. S., Covey D. F., Ostuni M. A., Lacapère J. J., Massaad C., Schumacher M., Steidl E. M., Maux D., Delaage M., Henderson C. E., Pruss R. M. (2007) J. Pharmacol. Exp. Ther. 322, 709–720 [DOI] [PubMed] [Google Scholar]
- 35.Olsen P. H., Esmon N. L., Esmon C. T., Laue T. M. (1992) Biochemistry 31, 746–754 [DOI] [PubMed] [Google Scholar]
- 36.Perkins S. J. (1986) Eur. J. Biochem. 157, 169–180 [DOI] [PubMed] [Google Scholar]
- 37.Howland D. S., Liu J., She Y., Goad B., Maragakis N. J., Kim B., Erickson J., Kulik J., DeVito L., Psaltis G., DeGennaro L. J., Cleveland D. W., Rothstein J. D. (2002) Proc. Natl. Acad. Sci. U.S.A. 99, 1604–1609 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Estévez A. G., Spear N., Thompson J. A., Cornwell T. L., Radi R., Barbeito L., Beckman J. S. (1998) J. Neurosci. 18, 3708–3714 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Hope M. J., Bally M. B., Webb G., Cullis P. R. (1985) Biochim. Biophys. Acta 812, 55–65 [DOI] [PubMed] [Google Scholar]
- 40.Barthélémy C., Henderson C. E., Pettmann B. (2004) BMC Neurosci. 5, 48. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Ricart K. J., Pearson R., Jr., Viera L., Cassina P., Kamaid A., Carroll S. L., Estévez A. G. (2006) J. Neurochem. 97, 222–233 [DOI] [PubMed] [Google Scholar]
- 42.Maroney A. C., Glicksman M. A., Basma A. N., Walton K. M., Knight E., Jr., Murphy C. A., Bartlett B. A., Finn J. P., Angeles T., Matsuda Y., Neff N. T., Dionne C. A. (1998) J. Neurosci. 18, 104–111 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Svensson A. K., Bilsel O., Kondrashkina E., Zitzewitz J. A., Matthews C. R. (2006) J. Mol. Biol. 364, 1084–1102 [DOI] [PubMed] [Google Scholar]
- 44.Pehar M., Cassina P., Vargas M. R., Castellanos R., Viera L., Beckman J. S., Estévez A. G., Barbeito L. (2004) J. Neurochem. 89, 464–473 [DOI] [PubMed] [Google Scholar]
- 45.Karch C. M., Prudencio M., Winkler D. D., Hart P. J., Borchelt D. R. (2009) Proc. Natl. Acad. Sci. U.S.A. 106, 7774–7779 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Mulligan V. K., Kerman A., Ho S., Chakrabartty A. (2008) J. Mol. Biol. 383, 424–436 [DOI] [PubMed] [Google Scholar]
- 47.Furukawa Y., Torres A. S., O'Halloran T. V. (2004) EMBO J. 23, 2872–2881 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Arnesano F., Banci L., Bertini I., Martinelli M., Furukawa Y., O'Halloran T. V. (2004) J. Biol. Chem. 279, 47998–48003 [DOI] [PubMed] [Google Scholar]
- 49.Hörnberg A., Logan D. T., Marklund S. L., Oliveberg M. (2007) J. Mol. Biol. 365, 333–342 [DOI] [PubMed] [Google Scholar]
- 50.Lindberg M. J., Normark J., Holmgren A., Oliveberg M. (2004) Proc. Natl. Acad. Sci. U.S.A. 101, 15893–15898 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Parge H. E., Hallewell R. A., Tainer J. A. (1992) Proc. Natl. Acad. Sci. U.S.A. 89, 6109–6113 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Tiwari A., Hayward L. J. (2003) J. Biol. Chem. 278, 5984–5992 [DOI] [PubMed] [Google Scholar]
- 53.Jonsson P. A., Graffmo K. S., Andersen P. M., Brännström T., Lindberg M., Oliveberg M., Marklund S. L. (2006) Brain 129, 451–464 [DOI] [PubMed] [Google Scholar]
- 54.Proescher J. B., Son M., Elliott J. L., Culotta V. C. (2008) Hum. Mol. Genet. 17, 1728–1737 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Carroll M. C., Outten C. E., Proescher J. B., Rosenfeld L., Watson W. H., Whitson L. J., Hart P. J., Jensen L. T., Cizewski Culotta V. (2006) J. Biol. Chem. 281, 28648–28656 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Okado-Matsumoto A., Fridovich I. (2002) Proc. Natl. Acad. Sci. U.S.A. 99, 9010–9014 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Deng H. X., Hentati A., Tainer J. A., Iqbal Z., Cayabyab A., Hung W. Y., Getzoff E. D., Hu P., Herzfeldt B., Roos R. P., Warner C., Deng G., Soriano E., Smyth C., Parge H. E., Ahmed A., Roses A. D., Hallewell R. A., Prericak-Vance M. A., Siddique T. (1993) Science 261, 1047–1051 [DOI] [PubMed] [Google Scholar]
- 58.Rumfeldt J. A., Lepock J. R., Meiering E. M. (2009) J. Mol. Biol. 385, 278–298 [DOI] [PubMed] [Google Scholar]
- 59.Khare S. D., Caplow M., Dokholyan N. V. (2004) Proc. Natl. Acad. Sci. U.S.A. 101, 15094–15099 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Cardoso R. M., Thayer M. M., DiDonato M., Lo T. P., Bruns C. K., Getzoff E. D., Tainer J. A. (2002) J. Mol. Biol. 324, 247–256 [DOI] [PubMed] [Google Scholar]
- 61.Lepock J. R., Frey H. E., Hallewell R. A. (1990) J. Biol. Chem. 265, 21612–21618 [PubMed] [Google Scholar]
- 62.Leinweber B., Barofsky E., Barofsky D. F., Ermilov V., Nylin K., Beckman J. S. (2004) Free Radic. Biol. Med. 36, 911–918 [DOI] [PubMed] [Google Scholar]
- 63.Prudencio M., Durazo A., Whitelegge J. P., Borchelt D. R. (2009) J. Neurochem. 108, 1009–1018 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Kayatekin C., Zitzewitz J. A., Matthews C. R. (2008) J. Mol. Biol. 384, 540–555 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Museth A. K., Brorsson A. C., Lundqvist M., Tibell L. A., Jonsson B. H. (2009) Biochemistry 48, 8817–8829 [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.